Abstract:Recent evidence shows that resveratrol (RSV) may ameliorate high-glucose-induced cardiac oxidative stress, mitochondrial dysfunction and myocardial fibrosis in diabetes. However, the mechanisms by which RSV regulates mitochondrial function in diabetic cardiomyopathy have not been fully elucidated. Mitochondrial dysfunction contributes to cardiac dysfunction in diabetic patients, which is associated with dysregulation of peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α). In this study we examined whether resveratrol alleviated cardiac dysfunction in diabetes by improving mitochondrial function via SIRT1-mediated PGC-1α deacetylation. T2DM was induced in rats by a high-fat diet combined with STZ injection. Diabetic rats were orally administered RSV (50 mg·kg –1 ·d –1 ) for 16 weeks. RSV administration significantly attenuated diabetes-induced cardiac dysfunction and hypertrophy evidenced by increasing ejection fraction (EF%), fraction shortening (FS%), ratio of early diastolic peak velocity (E velocity) and late diastolic peak velocity (A velocity) of the LV inflow (E/A ratio) and reducing expression levels of pro-hypertrophic markers ANP, BNP and β-MHC. Furthermore, manganese superoxide dismutase (SOD) activity, ATP content, mitochondrial DNA copy number, mitochondrial membrane potential and the expression of nuclear respiration factor (NRF) were all significantly increased in diabetic hearts by RSV administration, whereas the levels of malondialdehvde (MDA) and uncoupling protein 2 (UCP2) were significantly decreased. Moreover, RSV administration significantly activated SIRT1 expression and increased PGC-1α deacetylation. H9c2 cells cultured in a high glucose (HG, 30 mmol/L) condition were used for further analyzing the role of SIRT1/PGC-1α pathway in RSV regulation of mitochondrial function. RSV (20 μmol/L) caused similar beneficial effects in HG-treated H9c2 cells in vitro as in diabetic rats, but these protective effects were abolished by addition of a SIRT1 inhibitor sirtinol (25 μmol/L) or by SIRT1 siRNA transfection. In H9c2 cells, RSV-induced PGC-1α deacetylation was dependent on SIRT1, which was also abolished by a SIRT1 inhibitor and SIRT1 siRNA transfection. Our results demonstrate that resveratrol attenuates cardiac injury in diabetic rats through regulation of mitochondrial function, which is mediated partly through SIRT1 activation and increased PGC-1α deacetylation.

Sphingosine-1-Phosphate Receptor Agonist, Fty720, Restores Coronary Flow Reserve In Diabetic Rats

Protective effect of FTY720 on myocardial microvascular lesion in diabetic rat

Sustained Release of Stromal Cell-Derived Factor-1α from Injectable Hydrogels in Combination with Endothelial Progenitor Cells Effectively Promotes Neovascularization in Ischemic Diabetic Rats

Combined Treatment with Ultrasound-Targeted Microbubble Destruction Technique and NM-aFGF-loaded PEG-nanoliposomes Protects Against Diabetic Cardiomyopathy-Induced Oxidative Stress by Activating the AKT/GSK-3β1/Nrf-2 Pathway

Prevent Diabetic Cardiomyopathy in Diabetic Rats by Combined Therapy of Afgf-Loaded Nanoparticles and Ultrasound-Targeted Microbubble Destruction Technique.

GW25-e5344 Improvement of Left Ventricular Myocardial Perfusion after Acidic Fibroblast Growth Factor Delivered by Using Ultrasound-Targeted Microbubble Destruction in Diabetic Cardiomyopathy in Rats: an Preliminary Study

Functional and Pathological Improvements of the Hearts in Diabetes Model by the Combined Therapy of Bfgf-Loaded Nanoparticles with Ultrasound-Targeted Microbubble Destruction.

Advanced Interfere Treatment of Diabetic Cardiomyopathy Rats by Afgf-Loaded Heparin-Modified Microbubbles and UTMD Technique

Chronic inhibition of farnesyl pyrophosphate synthase improves endothelial function in spontaneously hypertensive rats.

Fty720 Protects Cardiac Microvessels of Diabetes: A Critical Role of S1p1/3 in Diabetic Heart Disease

Fenofibrate Improves Vascular Endothelial Function and Contractility in Diabetic Mice

Advanced Glycation End Product Blocker Drugs Have a Great Potential to Prevent Diabetic Cardiomyopathy in an Animal Model of Diabetes Mellitus Type-2

Therapeutic effects on the development of heart failure with preserved ejection fraction by the sodium-glucose cotransporter 2 inhibitor dapagliflozin in type 2 diabetes

Systematic Review and Meta-Analysis of the Efficacy of Sphingosine-1-Phosphate (S1P) Receptor Agonist FTY720 (Fingolimod) in Animal Models of Stroke

Sphingosine-1-Phosphate Receptor Modulator, FTY720, Improves Diastolic Dysfunction and Partially Reverses Atrial Remodeling in a Tm-E180G Mouse Model Linked to Hypertrophic Cardiomyopathy

Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKα/TGF‐β/Smad signalling in type 2 diabetic rats

PDE9A Inhibition Improves Coronary Microvascular Rarefaction and Left Ventricular Diastolic Dysfunction in the ZSF1 Rat Model of HFpEF

Evaluation of coronary function in female rats with severe type 1 diabetes: Effects of combined treatment with insulin and pyridoxamine

Resveratrol Alleviates Diabetic Cardiomyopathy in Rats by Improving Mitochondrial Function Through PGC-1α Deacetylation

Abstract 279: Stromal Cell-derived Factor-1 Prevents from Diabetic Cardiomyopathy Via Cxcr7/ampk-mediated Nrf2 Activation in Type 2 Diabetic Mice

Sildenafil and FDP-Sr Attenuate Diabetic Cardiomyopathy by Suppressing Abnormal Expression of Myocardial CASQ2, FKBP12.6, and SERCA2a in Rats.